Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Summit Technology/LCA-Vision

This article was originally published in The Gray Sheet

Executive Summary

Summit Technology/LCA-Vision: Summit agrees to divest its chain of photorefractive keratectomy (PRK) Vision Centers to LCA-Vision under an agreement announced July 23. Under the terms of the deal, LCA will issue about 17 mil. shares of its common stock for all of Refractive Centers International -- the Summit subsidiary which owns and operates the Vision Center business, including 19 centers across the U.S. The deal is valued at about $46.8 mil. based on LCA's July 22 closing price of 2-3/4. The transaction, still subject to standard regulatory conditions, also is awaiting "the closing of bank financing by LCA," Summit says. Summit announced its plan to either sell or spin off the business earlier this year due to its drain on company resources and its negative impact on customer relations with ophthalmic surgeons ("The Gray Sheet" Feb. 3, In Brief). Upon completion of the sale, LCA "will have over 40 vision correction centers in the U.S., Canada and Europe, making it one of the nation's largest providers of laser vision correction," Summit notes...

You may also be interested in...



Staar Surgical To Offer Ophthalmic Surgeons Stake In Laser-Center Chain

Staar Surgical will allow certain ophthalmic surgeons to purchase an equity stake in its chain of refractive laser eye surgery centers, the firm says.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel